← Back to Search

Monoclonal Antibodies

DLX105-DMP Multi-Dose Twice Weekly for Plaque Psoriasis

Phase 1
Waitlist Available
Research Sponsored by DelArrivo, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1, day 15, and day 25
Awards & highlights
No Placebo-Only Group

Summary

This trial tests DLX105-DMP on patients with mild-to-moderate plaque psoriasis to see if applying it to the skin can reduce symptoms like redness and scaliness.

Eligible Conditions
  • Plaque Psoriasis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1, day 15, and day 25
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1, day 15, and day 25 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Adverse Events
Local Investigator Global Assessment (IGA)
Local Psoriasis Area Severity Index Sum of Scores (Local PASI SOS)
+2 more
Secondary study objectives
Immunogenicity Testing
Pharmacokinetic Parameters

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: DLX105-DMP Multi-Dose Twice WeeklyExperimental Treatment1 Intervention
4 Weeks of 1mg DLX105-DMP applied to a target lesion twice weekly
Group II: DLX105-DMP Multi-Dose Once WeeklyExperimental Treatment1 Intervention
4 Weeks of 1mg DLX105-DMP applied to a target lesion once weekly
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
DLX105-DMP
2022
Completed Phase 1
~10

Find a Location

Who is running the clinical trial?

DelArrivo, Inc.Lead Sponsor
~3 spots leftby Nov 2025